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BENZODIAZEPINE PRESCRIBING PATTERNS AND DRUG OVERDOSE 
DEATHS AMONG INDIVIDUALS RECEIVING OPIOID ANALGESICS 
TAE WOO PARK 
ABSTRACT 
Objective: To study the association between benzodiazepine prescribing patterns 
including dose, type and dosing schedule and the risk of drug overdose death among US 
veterans receiving opioid analgesics. 
Design: Case-cohort study  
Setting: Veterans Health Administration (VHA), 2004 through 2009. 
Participants: US veterans, primarily male, who received opioid analgesics between 2004 
and 2009. All veterans who died of a drug overdose (n = 2,400) while receiving opioid 
analgesics and a random sample of veterans (n = 420,386) who received VHA medical 
services and opioid analgesics were included in the study.  
Main outcome measure: Drug overdose death, defined as any intentional, unintentional 
or indeterminate poisoning death caused by any medication or drug, determined by cause 
of death information from the National Death Index.  
Results: Twenty seven percent of veterans who received opioid analgesics also received 
benzodiazepines during the study period. Approximately half of the drug overdose deaths 
(n=1,185) occurred when veterans were concurrently prescribed benzodiazepines and 
opioids. Risk of drug overdose death increased based on benzodiazepine prescription 
history: formerly prescribed vs. not prescribed (adjusted hazard ratio [HR]=2.33, 95% 
confidence interval [CI]: 2.05–2.64); currently prescribed vs. not prescribed (HR=3.86, 
  v 
CI:3.49–4.26). Risk of drug overdose death increased as daily benzodiazepine dose 
increased. When compared to clonazepam, temazepam was associated with a decreased 
drug overdose death risk (HR=0.63, CI: 0.48–0.82). Benzodiazepine dosing schedule was 
not associated with drug overdose death risk.  
Conclusions: Among veterans receiving opioid analgesics, receipt of benzodiazepines 
was associated with an increased risk of drug overdose death in a dose-response fashion.  
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INTRODUCTION 
 
Benzodiazepines are a class of medications largely used for their anxiolytic, 
sedative, and hypnotic effects. Through binding of benzodiazepine receptors in the brain, 
benzodiazepines enhance the inhibitory effects of the neurotransmitter gamma-
aminobutyric acid and can reduce anxiety (anxiolytic effect), produce calm (sedative 
effect), and induce sleep (hypnotic effect). Due to these abilities, benzodiazepines were 
among the most widely prescribed medications in the United States for several decades.1 
The use of these medications began to decrease after their peak popularity in the late 
1970’s, in large part due to concerns of their side effects. These side effects include 
oversedation, cognitive impairment and psychomotor incoordination. Additionally, long 
term benzodiazepine use can lead to physical dependence. Benzodiazepines have the 
potential to be abused, although the abuse potential is considered low.2     
Although the use of benzodiazepines has decreased in the general population, they 
are still commonly prescribed for patients who receive opioid analgesic medications for 
chronic pain. The primary indication for benzodiazepines in chronic pain patients is for 
pain relief in those with chronic back pain.3 Benzodiazepines are also prescribed in this 
patient population to treat anxiety and insomnia. Anxiety disorders commonly co-occur in 
patients with chronic pain4 and insomnia is one of the most common complaints of 
chronic pain patients.5 Recent studies indicate that 25 to 43% of chronic pain patients 
who are prescribed chronic opioids are also prescribed benzodiazepines concurrently.6–8 
Patients taking concurrent benzodiazepines and opioid analgesics are more likely to be 
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depressed,9 have higher rates of substance use disorders,7 and have been taking 
benzodiazepines for longer periods of time than those taking opioids alone.7 
Despite its potential efficacy in treating symptoms of pain disorders, the practice 
of co-prescribing benzodiazepines in patients receiving chronic opioids is also believed to 
carry risks. The primary concern is the risk of drug overdose. Although the toxicity of 
benzodiazepines used in isolation is generally considered mild in young and middle-aged 
adults, the risks from oversedation are believed to be magnified when combined with 
other substances with sedating properties, such as opioids.8,10 Drug overdose deaths, 
particularly involving opioid analgesics, have increased steadily over the past two 
decades and is now one of the leading causes of injury mortality in the United States.11 Of 
the pharmaceutical-related overdose deaths, which constituted 58% of total drug overdose 
deaths in 2010, 75% involved opioid analgesics.12 Thirty percent of opioid analgesic-
related overdose deaths involved benzodiazepines. Between 2006 and 2011, opioid 
analgesic-related overdose deaths involving benzodiazepines increased by 14% on 
average each year, while overdose deaths not involving benzodiazepines did not change 
significantly.13 Also, receipt of benzodiazepines may be a marker of the presence of a 
significant anxiety disorder, which likely carries its own risk for intentional and 
unintentional overdose death.14,15 
Trends in overdose deaths have been connected to patterns of opioid prescribing, 
an increasingly common treatment for pain.16 On a population level, increasing rates of 
opioid prescribing have been linked to an increased rate of overdose death17; on an 
individual level, the risk of overdose death is higher among those receiving higher doses 
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of opioids.6, 18 Two recent studies that examined the relationship between opioid 
analgesics and overdoses found that the prescription of sedative-hypnotics, a group of 
drugs that include benzodiazepines, in patients who also received opioid analgesics were 
associated with a greater likelihood of overdose.6,11 Dunn et al., in a retrospective cohort 
study that utilized patient and pharmacy data from a health maintenance organization in 
Washington state, calculated the number of days’ supply of sedative-hypnotics in 90 day 
exposure windows for each patient. They found that compared to those not receiving 
sedative-hypnotics, patients who had received sedative-hypnotics were more likely to 
have a fatal or non-fatal overdose. This relationship did not depend on the quantity of 
days supply. Paulozzi et al., in a case control study that utilized data from New Mexico’s 
prescription monitoring program and the state’s medical examiner’s office, found that one 
or more sedative-hypnotic prescriptions during the study period were associated with an 
increased odds of fatal overdose.  
Since Dunn et al. and Paulozzi et al. did not focus primarily on the effect of co-
prescribed benzodiazepines on overdose, further research on the impact of 
benzodiazepines is warranted. First, neither study addressed the potential for confounding 
by indication and severity with rigor. Given benzodiazepines are often prescribed for 
patients with mental health disorders, particularly anxiety and depression, and both are 
associated with an increased risk of overdose death14, it is possible that the impact on 
overdose can be attributed to the presence of anxiety and/or depression and the severity of 
those illnesses rather than to the benzodiazepine itself. Second, definitions for concurrent 
or concomitant use of 2 or more medications can vary in the pharmacoepidemiology 
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literature – from exposures that overlap (utilizing prescription details such as date of 
prescription and days’ supply) to more broad definitions such as prescriptions for 
different medications that occur during the study period. Both the Dunn et al. or Paulozzi 
et al. studies used broad definitions of concurrent use which may have biased the effect of 
sedative-hypnotics towards an increased overdose risk, particularly if individuals who 
tend to be prescribed sedative-hypnotics are at increased risk of overdose. Additionally, 
the Dunn et al. and Paulozzi et al. did not examine the effect of benzodiazepine dose, 
benzodiazepine type or benzodiazepine schedule (regularly scheduled vs. as needed) on 
overdoses. The independent toxic effect of benzodiazepines, when used in overdoses that 
involved benzodiazepines, has been found to vary by benzodiazepine type19. Risk of 
injury in the elderly associated with benzodiazepines, typically caused by falls, has been 
found to vary by benzodiazepine type, dose, and schedule.20–22 Thus the prescribing 
patterns of the concurrently prescribed benzodiazepines may have an impact on overdose 
risk in patients receiving prescription opioids. The Dunn et al. study included both non-
fatal and fatal overdoses. Of the 51 overdoses in that study, 6 were fatal. Both non-fatal 
and fatal overdoses are of public health interest. Lastly, both Dunn et al. and Paulozzi et 
al. utilized a single state or health maintenance organization’s patient data. A nationwide 
study with a larger sample size may increase generalization of study findings and allow 
for better exploration of subgroups of patients.  
The aim of this study is to describe the relationship between the receipt of 
concurrent benzodiazepines and opioid analgesics and drug overdose death in patients 
receiving prescription opioids for the treatment of acute, chronic and cancer pain. 
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Quantifying the magnitude of risk associated with these patterns might help identify 
individuals at particularly high risk for drug overdose death and could potentially inform 
risk-reduction approaches in this population. We used a case-cohort study design to 
examine the relationship of benzodiazepine prescription history, dose, type and schedule 
with risk of drug overdose death over a 6-year period among a nationwide sample of 
patients who received treatment with opioid analgesics in the Veterans Health 
Administration (VHA).  
 
Study objectives: 
1. To describe the relationship between receipt of benzodiazepines and the incidence 
of drug overdose death in patients receiving opioid analgesics 
2. To evaluate whether different benzodiazepine prescribing patterns such as 
benzodiazepine dose, type and schedule affect the relationship between 




1. Benzodiazepine receipt is associated with an increased risk of drug overdose death 
in patients receiving opioid analgesics  
Secondary 
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1. Current benzodiazepine receipt will be more strongly associated with an increased 
risk of drug overdose death than past benzodiazepine receipt in patients receiving 
opioid analgesics  
2. Higher doses of benzodiazepines are more strongly associated with increased risk 
of drug overdose death than lower doses of benzodiazepines in patients treated 
with prescription opioid analgesics 
3. Type of benzodiazepine is associated with drug overdose death in patients 
receiving opioid analgesics 
4. Benzodiazepines received on an as needed basis will be associated with increased 
risk of drug overdose death compared to receipt of regularly scheduled 
benzodiazepines in patients receiving opioid analgesics 
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METHODS 
 
Study design and population 
This study utilized a case-cohort study design.23 Similar to a nested case-control 
study, cases and controls are sampled from the same source population. Controls in the 
case-cohort design are randomly sampled and, unlike a nested case-control study, 
matching typically does not occur. Cases and controls in this study were sampled from a 
source population that consisted of veterans who received Veterans Health 
Administration (VHA) medical services and opioid analgesic medications as an 
outpatient between fiscal years (FY) 2004–2009. The VHA is the largest integrated health 
care system in the US, serving nearly nine million veterans across over 150 hospitals and 
over 800 community-based outpatient centers throughout the US. There were 2,400 cases 
which included all drug overdose deaths that occurred while receiving opioid analgesics 
and 420,386 controls which included 5% annual random samples of the source population 
during the study period. We attempted to limit the analysis to veterans receiving 
prescription opioids for the treatment of acute, chronic and non-terminal cancer pain by 
excluding 221 veterans who received methadone prescriptions received for maintenance 
purposes and 5,816 veterans with indicators of palliative care consultations or hospice 
care. The final sample size for this study was 422,786. Immortal time bias occurs when 
there is a period, the immortal time, between study entry and date of first exposure during 
which the outcome cannot occur. This bias is common in pharmacoepidemiological 
studies. 24 In our study, the start of observation for both cases and controls was the date of 
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the first opioid analgesic fill after the first medical visit of the year within the study 
period. Study entry was not dependent on exposure to benzodiazepines and outcome 
events could occur in the period of time between study entry and first exposure to 
benzodiazepines. Thus, no immortal time bias exists in our study. Observation for 
controls ended either when the veteran died of any cause or at the end of FY09, 
whichever occurred first.  
 
Data sources  
We used data abstracted from the electronic medical records of VHA patients. 
This included demographic and clinical encounter data from the VHA’s National Patient 
Care Database. Outpatient prescription data was collected from the VHA’s Pharmacy 
Benefits Management (PBM) Services and consisted of records of filled prescriptions 
(which included the fill date, days supply, and schedule). Cause of death information was 
obtained from the National Death Index (NDI).25 Matching with the NDI for our sample 
used two methods: 1) a full match on the 9-digit Social Security number (SSN) and sex 
and match on at least 2 of the 3 parts (day, month, year) of date of birth; or 2) match on at 
least 7 digits of the SSN plus full match on date of birth, sex, first name, and last name 
and middle initial when present. More than 99% of deaths among VHA patients had a full 
match on SSN. Study procedures received approval from the Ann Arbor VA human 
studies committee, which waived the requirement for informed consent.     
 
Drug overdose deaths 
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The NDI reports cause of death using codes from the International Statistical 
Classification of Diseases, Tenth Revision (ICD-10). Cause of drug overdose death can 
be classified as unintentional (X40-45), intentional (X60-65) or indeterminate (Y10-15) 
and specific drugs involved may be listed with a T-code.26 Of the 43,982 drug overdose 
deaths in the US in 2013, 81.1% were classified as unintentional, 12.4% intentional, and 
6.4% indeterminate.27 Because intent is often difficult to determine, particularly in 
poisoning deaths28, and a significant proportion of death certificates do not specify the 
drug(s) involved,12 we defined our drug overdose outcome as any intentional, 
unintentional or indeterminate overdose death caused by any medication or drug (X40-45, 
X60-65, Y10-15, without T-code specified). 
 
Medication prescribing patterns 
Oral benzodiazepine and opioid analgesic prescriptions filled on an outpatient 
basis were examined in this study. Since individuals with indications for benzodiazepines 
may be at higher risk of overdose death14, we distinguished periods during which 
individuals were currently receiving benzodiazepines from periods when they had 
formerly received them in order to help address unmeasured confounding.29 Every 
person-day was classified according to each veteran's benzodiazepine prescription history, 
categorized as current, former, or none. "Current" receipt time accumulated starting with 
a benzodiazepine prescription fill and continued through the end of the fill, as determined 
by the days supply. If another fill was received, current receipt time continued to 
accumulate. "Former" receipt time accumulated starting at the end of a current 
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benzodiazepine prescription fill and continued through to the end of the study period, 
unless another benzodiazepine prescription was filled, at which time the fill again 
contributed to current receipt time. Periods prior to a veteran’s first benzodiazepine fill or 
periods for those who never received a benzodiazepine were labeled “none”. With regards 
to each veteran’s opioid prescription history, every person-day was classified as “current” 
or “none.” Only days classified as current opioid receipt were included in this study. 
Benzodiazepine types included in the study were alprazolam, chlordiazepoxide, 
clonazepam, diazepam, lorazepam, temazepam, estazolam, flurazepam, oxazepam, 
quazepam, and triazolam. The most commonly prescribed benzodiazepines were those on 
the VHA drug formulary, which consisted of alprazolam, chlordiazepoxide, clonazepam, 
diazepam, lorazepam, and temazepam. The other benzodiazepines included in the study 
were prescribed during the study period, but at lower rates. Benzodiazepine dose was 
calculated as diazepam equivalents, according to previously published conversion 
tables.30 Benzodiazepine schedule was classified as regularly scheduled, as-needed, or 
simultaneous regularly scheduled and as-needed. Opioid analgesics included in this study 
were codeine, morphine, oxycodone, hydrocodone, oxymorphone, hydromorphone, 
fentanyl, propoxyphene and methadone. Methadone prescriptions in this study were 
limited to those prescribed to treat pain by excluding prescriptions in which 1) dosing 
instructions indicated the methadone was prescribed for maintenance, 2) oral or 
effervescent methadone formulations were prescribed unless the dosing schedule 
indicated more than once a day dosing, or 3) the dosing schedule was once a day unless 
the instructions indicated the methadone was prescribed for pain. Buprenorphine is not 
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currently indicated for pain treatment in the VHA and was not included in this analysis. 
Opioid analgesic dose was calculated as morphine equivalents.31, 32 
Both benzodiazepine and opioid analgesic dose were measured using an “as-
prescribed” approach, which assumes that patients took their benzodiazepines and opioid 
analgesics according to the prescribers’ instructions.33 Patients were assumed to be taking 
the maximum amount described in the prescription, including for “as-needed” 
prescriptions. Dose was calculated by adding all diazepam or morphine milligram (mg) 
equivalents in each prescription and dividing by the number of days supply. This dose 
represented the maximum daily dose prescribed and not necessarily the amount actually 
consumed. If there was an overlap between two prescriptions of the same drug at the 
same dose and schedule, it was assumed that the first prescription was finished before the 
second prescription was started rather than assuming a higher amount of medication was 
taken during the overlap. If the overlapping drugs were of a different type, dose or 
schedule, than the second fill was assumed to have started on the date it was filled. Both 
benzodiazepine and opioid analgesic dose were treated as time-varying.  
 
Covariates 
We obtained demographic and diagnostic data from patient records. Demographic 
data included age, sex, and race. Race was classified as white, black, other, or missing/not 
recorded. Additionally, each veteran’s zip code of residence was linked to US Census 
data to obtain the percentage of people living below the federal poverty line in that zip 
code as a proxy measure for socioeconomic status.34 Zip code data was missing in 4.3% 
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of the sample and poverty data was imputed using simple imputation by logistic 
regression. The socioeconomic status variable was categorized into quintiles. All 
diagnoses were made during the year prior to each veteran’s start of observation. 
Diagnoses were categorized into substance use disorders, PTSD, other anxiety disorders, 
depressive disorders, and bipolar or psychotic disorders. Additionally, we measured 
medical comorbidity using the Charlson comorbidity score.35 In order to assess mental 
health and substance use disorder acuity, the number of mental health and substance use 
disorder-related hospitalizations determined by VHA bed section codes in the year prior 
to start of observation was also measured. Use of other medications was assessed by 
examining the receipt of three categories of medications in the year prior to start of 
observation: 1) antidepressants, 2) antiepileptic and anti-parkinsonism drugs, and 3) 
antipsychotic and neuroleptic drugs. These categories were the three most commonly 
identified classes of pharmaceuticals after benzodiazepines involved in opioid-related 
overdose deaths in the United States in 201012. 
 
Statistical analysis 
We compared baseline patient characteristics between those who received 
benzodiazepines during the study period and those who did not receive benzodiazepines 
with chi-square tests (Table 1).  
We calculated overdose death rates for veterans’ benzodiazepine prescription 
history, dose, type and schedule (Table 2). The denominator for all rates (person-years) 
was adjusted to account for the case-cohort design by multiplying the observation time 
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accumulated for the cohort by the inverse of the sampling fraction.  Consequently, all 
rates are estimates for the entire source population.  
We used Cox proportional hazards models to calculate hazard ratios (HRs) for 
current and former receipt of benzodiazepines, compared to no receipt. All HRs were 
adjusted for all covariates, including time-varying opioid analgesic dose. We used a risk-
set approach and a robust variance estimator for all multivariable modeling.36  
Our primary analysis (Model 1, Table 3) studied the association between 
benzodiazepine prescription history and overdose death. In our primary analysis, we 
tested for an interaction between benzodiazepine prescription history and opioid dose. 
Secondarily, we studied the association between benzodiazepine dose, type and schedule 
and overdose death only during times when veterans were currently receiving 
benzodiazepines and opioid analgesics concurrently (Model 2, Table 3). In order to 
demonstrate that any association between opioid dose and overdose death is not due to 
confounding by benzodiazepine prescription history, we examined the association 
between opioid dose and overdose stratified by benzodiazepine prescription history 
(Table 4).  
Several sensitivity analyses were conducted. We examined the association 
between benzodiazepine prescription history and overdose death not known to be 
intentional, by defining a modified overdose death outcome that excluded overdose 
deaths coded as intentional. We also examined the association between benzodiazepine 
prescription history and opioid/benzodiazepine-attributable overdose death by defining a 
modified overdose death outcome that included only deaths attributed to opioids and/or 
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benzodiazepines (ICD-10 codes X41, X42, X44, X61, X62, X64, Y11, Y12, Y14 in 
combination with T40.2, T40.3, T40.4, T40.6 or T42.4). We examined the association 
between benzodiazepine prescription history and overdose death in a cohort that excluded 
patients with a cancer diagnosis in the year prior to observation (except for non-
melanoma skin cancer). Since patients may not take all of their medications during the 
days supply described in the prescription, we expanded the periods during which patients 
were currently receiving benzodiazepines by 10% of the days supply (for example, a 30 
day supply would be expanded to 33 days). 
Analyses were conducted using SAS version 9.3 (SAS Institute, Cary, North 
Carolina). 




Of the 422,786 veterans in the study population, 112,069 (27%) had filled at least 
one benzodiazepine prescription during the study period (Table 1). Those who received 
benzodiazepines were more likely to be female, middle-aged, white, and reside in 
wealthier areas. Additionally, they were more likely to have had a recent mental health or 
substance use disorder-related hospitalization, a diagnosis of a substance use disorder or a 
number of psychiatric disorders, including PTSD, other anxiety disorders, depression, and 
bipolar or psychotic disorders, and use other medications.  
 
Table 1. Characteristics of the Sample of Veterans Health Administration Patients 
Who Received Opioid Analgesics Between Fiscal Year 2004–2009 by Receipt of 
Benzodiazepine 
 








Male 291,070 (94) 102,252 (91) 
Age    
  18–29 9,256 (3) 2,639 (2) 
  30–39 15,053 (5) 5,791 (5) 
  40–49 35,961 (12) 15,841 (14) 
  50–59 83,772 (27) 38,471 (34) 
  60–69 77,147 (25) 25,366 (23) 
  ≥70 89,528 (29) 23,961 (21) 
Race   
  Black 57,286 (18) 12,600 (11) 
  White 217,663 (70) 89,764 (80) 
  Other/missing 35,768 (12) 9,705 (9) 
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ap<0.001 for all between-group comparisons 
bAll conditions and events were measured in the year up to and including the day of the 
first opioid fill during the observation period and are not mutually exclusive 
 
 
Unadjusted rates of drug overdose death 
 
Of the 2,400 veterans in the study population who died of a drug overdose while 
receiving opioid analgesics, 1,185 (49%) died during a period in which they had been 
prescribed concurrent benzodiazepines (Table 2). Unadjusted rates of drug overdose 
death were higher during periods when veterans currently received benzodiazepines than 








Hispanic ethnicity 14,285 (5) 5,470 (5) 
Area level poverty by quintiles   
  1 (Wealthiest) 61,992 (20) 22,565 (20) 
  2 61,741 (20) 22,853 (20) 
  3 61,377 (20) 23,140 (21) 
  4 61,465 (20) 23,113 (21) 
  5 (Poorest) 64,142 (21) 20,398 (18) 
Substance use disorder (SUD)b 29,544 (10) 14,712 (13) 
Recent mental health or SUD-related 
hospitalizationb 
4,607 (1) 4,798 (4) 
Post-traumatic stress disorderb 27,995 (9) 24,759 (22) 
Other anxiety disorderb 15,266 (5) 22,369 (20) 
Depressionb 58,627 (19) 42,827 (38) 
Bipolar/psychotic disorderb 13,587 (4) 11,795 (11) 
Cancerb 73,929 (24) 25,821 (23) 
Charlson comorbidity indexb   
  0 129,358 (42) 44,003 (39) 
  1 73,260 (24) 27,448 (24) 
  ≥2 108,099 (35) 40,618 (36) 
Receipt of other medicationsb   
  Antidepressants 96,557 (31) 65,547 (58) 
  Antiepileptic and anti-parksonism drugs 72,630 (23) 43,063 (38) 
  Antipsychotic and neuroleptic drugs 32,734 (11) 27,817 (25) 
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in those when veterans formerly received them or had not received them at all. 
Unadjusted overdose death rates increased at consecutively higher daily benzodiazepine 
dose categories. Periods during which veterans received lorazepam and temazepam had 
lower overdose death rates than periods involving the other benzodiazepine types. 
Overdose death rates were higher in periods in which benzodiazepines were 
simultaneously prescribed regularly scheduled and as-needed medications compared to 
the other schedules.  
 
Table 2. Unadjusted rate of drug overdose death by benzodiazepine prescription 









Rate per 100,000 
Person-Years 
(95% CI)a 
Benzodiazepine prescription history    
  None 794 1,116,346 71 (66, 76) 
  Former 421 225,171 187 (170, 205) 
  Current 1185 375,332 316 (298, 334) 
Daily benzodiazepine dose, mg/d    
  0 421 376,645 112 (101, 123) 
  >0–10 241 158,676 152 (133, 172) 
  >10–20 366 121,411 301 (271, 333) 
  >20–30 237 45,718 518 (454, 586) 
  >30–40 169 28,170 600 (513, 694) 
  >40 172 21,357 805 (689, 930) 
Benzodiazepine type    
  Clonazepam 288 76,017 379 (336, 424) 
  Diazepam 276 72,444 381 (337, 427) 
 








Rate per 100,000 
Person-Years 
(95% CI)a 
Benzodiazepine type    
  Alprazolam 182 63,155 288 (248, 332) 
  Lorazepam 110 64,587 170 (140, 204) 
  Temazepam 88 57,301 154 (123, 187) 
  Other 20 6,464 309 (189, 459) 
  Multiple 221 35,365 625 (545, 710) 
Benzodiazepine schedule    
  Regularly scheduled only 449 169,515 265 (241, 290) 
  As needed only 638 190,933 334 (309, 361) 
  Simultaneous as needed and regularly 
scheduled 
98 14,884 658 (535, 795) 
Abbreviation: CI, confidence interval 
aUnadjusted overdose rates are estimates for the entire source population 
 
When the overdose death rates were stratified by daily opioid dose categories 
(Figure 1), the difference in rates between periods of current and former benzodiazepine 
receipt was not significant at the lowest opioid dose category but was significant at higher 
opioid dose categories. 
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Figure 1. Unadjusted drug overdose death rates by benzodiazepine prescription 
history and daily opioid dose 
 
Abbreviations: mg, milligram; d, day 
Error bars represent 95% confidence intervals 




Compared to periods in which veterans had not received benzodiazepines, periods 
of current benzodiazepine receipt (hazard ratio = 3.86; 95% confidence interval [CI], 
3.49–4.26) and former benzodiazepine receipt (HR = 2.33; 95%CI, 2.05–2.64) were 
associated with an increased risk of overdose death (Table 3). The interaction between 
benzodiazepine history and opioid dose was not statistically significant (p=0.60), 
indicating that the relationships between benzodiazepine prescription and opioid dose and 
overdose death were neither greater nor less than additive. Higher benzodiazepine dose 
categories were associated with greater risk of overdose death. Temazapam (HR = 0.63; 
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95%CI, 0.48–0.82) was found to have an association with decreased overdose death risk 
compared to the most commonly prescribed benzodiazepine, clonazepam. All other 
benzodiazepines had similar risk when compared to clonazepam. No association between 
benzodiazepine dosing schedule with overdose death was found after adjustment.  
Table 3. Adjusted hazard ratios of drug overdose deaths by benzodiazepine 
prescription history, daily benzodiazepine dose, benzodiazepine type, and 
benzodiazepine schedule 
 
 Hazard ratio 95% CI 
 Model 1a  
Benzodiazepine prescription history   
  None 1.00 (reference) - 
  Former 2.33 2.05–2.64 
  Current 3.86 3.49–4.26 
 Model 2b  
Daily benzodiazepine dose, mg/d   
  >0–10 1.00 (reference) - 
  >10–20 1.69 1.42–2.01 
  >20–30 2.34 1.91–2.86 
  >30–40 2.65 2.10–3.33 
  >40 3.06 2.38–3.92 
Benzodiazepine type   
  Clonazepam 1.00 (reference) - 
  Alprazolam 0.93 0.75–1.14 
  Diazepam 0.93 0.77–1.13 
  Lorazepam 0.79 0.62–1.00 
  Temazepam 0.63 0.48–0.82 
  Other 1.09 0.67–1.77 
  Multiple 1.05 0.83–1.33 
Benzodiazepine schedule   
  Regularly scheduled 1.00 (reference) - 
  As needed only 0.98 0.86–1.13 
  Simultaneous as needed and regularly scheduled 1.07 0.80–1.43 
Abbreviations: CI, confidence interval 
aModel 1 adjusted for sex, age, race, ethnicity, area level poverty, time-varying daily 
opioid dose, recent SUD-related hospitalization, Charlson comorbidity index, diagnosis 
of substance use disorder, post-traumatic stress disorder, other anxiety disorder, 
depression, bipolar/psychotic disorder, and cancer, and use of other medications 
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After stratifying by benzodiazepine prescription history, compared to the lowest 
opioid dose category, higher opioid dose categories were associated with increasingly 
greater risk of overdose death during periods of no benzodiazepine receipt, former 
benzodiazepine receipt, and current benzodiazepine receipt (Table 4). 
 
Table 4. Adjusted hazard ratios of drug overdose deaths by daily opioid dose, 
stratified by benzodiazepine use historya 
 
 Hazard ratio 95% CI 
 No benzodiazepine receipt  
Daily opioid dose   
  >0–<20 mg 1.00 (reference) - 
  20–<50 mg 1.57 1.28–1.91 
  50–<100 mg 2.81 2.26–3.50 
  ≥100 mg 3.30 2.62–4.16 
 Former benzodiazepine receipt  
Daily opioid dose   
  >0–<20 mg 1.00 (reference) - 
  20–<50 mg 1.17 0.86–1.60 
  50–<100 mg 2.33 1.69–3.21 





Daily opioid dose   
  >0–<20 mg 1.00 (reference) - 
  20–<50 mg 1.54 1.24–1.90 
  50–<100 mg 2.95 2.37–3.66 
  ≥100 mg 3.92 3.17–4.85 
Abbreviations: CI, confidence interval 
aSeparate models were created for each daily opioid dose category adjusting for sex, age, 
race, ethnicity, area level poverty, time-varying daily opioid dose, recent SUD-related 
hospitalization, Charlson comorbidity index, diagnosis of substance use disorder, post-
traumatic stress disorder, other anxiety disorder, depression, bipolar/psychotic disorder, 
and cancer, and use of other medications 
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Sensitivity analyses 
We conducted several sensitivity analyses in order to test the robustness of the 
results of our primary analysis (Table 5). We found that the exclusion of intentional 
overdose deaths, overdose deaths without mention of opioids or benzodiazepines, people 
with cancer, and an expansion of the periods during which patients were currently 
prescribed benzodiazepines (carryover period) resulted in only minor differences in the 
degree of association between benzodiazepine prescription history and overdose death, 
and no substantive differences in the inferences drawn from analyses. 
 
Table 5. Sensitivity analysesa 
  









  None 1.00 (reference) - 
  Former 2.23 1.95–2.56 
  Current 3.81 3.42–4.24 
 
Overdose deaths mention  






  None 1.00 (reference) - 
  Former 2.49 2.12–2.93 
  Current 3.86 3.39–4.41 
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  None 1.00 (reference) - 
  Former 2.50 2.16–2.89 
  Current 4.06 3.62–4.57 




  None 1.00 (reference) - 
  Former 2.30 2.02–2.61 
  Current 3.81 3.45–4.22 
Abbreviations: CI, confidence interval 
aSeparate models were created for each daily opioid dose category adjusting for sex, age, 
race, ethnicity, area level poverty, time-varying daily opioid dose, recent SUD-related 
hospitalization, Charlson comorbidity index, diagnosis of substance use disorder, post-
traumatic stress disorder, other anxiety disorder, depression, bipolar/psychotic disorder, 
and cancer, and use of other medications 
 




We found that receipt of concurrent benzodiazepines was associated with an 
increased risk of overdose death in this large, national sample of veterans who received 
opioid analgesics. Notably, approximately half of the overdose deaths occurred while 
veterans were receiving concurrent benzodiazepines and opioids. Benzodiazepine dose 
was also found to be associated with an increased risk of overdose death in a dose-
response fashion. Current receipt of benzodiazepines was associated with a greater 
magnitude of risk than former receipt. Temazepam was associated with a decreased risk 
of overdose death compared to clonazepam. No other benzodiazepine type differed from 
clonazepam in their relationship with overdose death risk. Benzodiazepine schedule was 
not associated with an increased risk of overdose death. The associations found in this 
study remained significant in analyses adjusting for potential confounders.  
 
Strengths and weaknesses of the study 
The strengths of this study included the large size of the study cohort and the 
ability to study a national sample of patients from the largest health system in the United 
States. Patients in the VHA are present in every state in the US, in both rural and urban 
areas. This large, national sample allows for subgroup analyses, such as the sensitivity 
analyses that we conducted in this study. Additionally, we were able to adjust for a range 
of patient-level variables. These included demographic, socioeconomic, and medical and 
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mental health diagnostic data. The wide range of variables may have helped reduce the 
amount of confounding in our study findings. Although we studied a large, national 
cohort, all study participants were US veterans and most were male; both of which are 
characteristics associated with accidental poisoning mortality.37 This may limit the 
generalizability of the study. Because we only examined treatment received within the 
VHA in this study, we may not have captured encounters that could affect overdose death 
risk, such as medications received from non-VHA prescribers. Additionally, since our 
daily dose calculations for benzodiazepines and opioid analgesics assume that veterans 
take medications exactly as prescribed, we may not have accurately measured the amount 
of medications taken on any given day. Veterans may have retained medications beyond 
the period they were prescribed for or received additional medications from non-VHA 
prescribers and subsequently took larger doses than indicated by the prescribers’ 
instructions. If this behavior is associated with receiving benzodiazepines and with 
overdose death, then our effect estimates may have been inflated. Because VHA 
pharmacy data are not linked to indications or diagnoses, we were unable to ascertain the 
indications for which the benzodiazepines were prescribed. Thus, we are unable to know 
if the association between benzodiazepine prescription and overdose death differs by 
indication or draw inferences to patients with specific indications. We did not account for 
potential clustering due to variation in practice among clinical sites. It is possible that 
adjusting for site variation in benzodiazepine prescribing may reduce our effect estimates. 
Additionally, because we did not have access to data on alcohol use, a drug with similar 
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effects as benzodiazepines, we were unable to adjust for alcohol use in our analysis and 
thus may have confounded our results. 
 
Strengths and weaknesses in relation to other studies 
The findings of this study were largely consistent with studies that have suggested 
that there are risks associated with concurrent benzodiazepine and opioid use. Dunn et 
al.13 found an association between receipt of sedative-hypnotic medications and increased 
risk of combined fatal and non-fatal overdoses. This study utilized data from a health 
maintenance organization in Washington state. They did not find a relationship between 
the days supply of sedative-hypnotics and risk of overdose. The large majority of the 
overdoses in the Dunn et al. study were non-fatal. Paulozzi et al. found an association 
between sedative-hypnotic prescriptions and an increased risk of overdose death. This 
study utilized data from New Mexico state’s prescription monitoring program and the 
state’s medical examiner’s office. Although the study adjusted for basic demographic data 
on participants, it lacked data that described socioeconomic and diagnostic participant 
characteristics. Other studies have looked at smaller subgroups of patients taking opioid 
analgesics. In a Swedish study that utilized that country’s national health registry and was 
limited to patients with severe respiratory disease, receipt of concurrent benzodiazepines 
and opioid analgesics was associated with increased risk of total mortality.38 In a study of 
US veterans with post-traumatic stress disorder, receipt of concurrent benzodiazepines 
and opioid analgesics, combined with antidepressants, was found to be associated with 
increased risk of adverse events which included injuries, emergency department visits, 
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and hospitalizations.39 Our study extends this literature in several ways. We studied a 
much larger, nationwide sample focusing exclusively on benzodiazepine prescribing 
patterns and their association with fatal overdoses. We also examined the association 
between benzodiazepine prescribing practices (dose, type and schedule) and overdose 
death risk. We found a dose-dependent relationship between benzodiazepine dose and 
overdose death, and also were able to more rigorously address issues of confounding in 
our analysis due to the larger sample size. 
 
Meaning of the study 
In this study, there was likely confounding by indication and confounding by 
severity.40 These biases are common in pharmacoepidemiological studies because 
patients who receive a specific medication often have different characteristics than 
patients who don’t receive that medication and these different characteristics may be 
associated with the study outcome. For example in this study, benzodiazepines were more 
likely to be prescribed to those with substance use and other psychiatric disorders such as 
anxiety, conditions which carry their own risk for overdose death.14 Additionally, 
benzodiazepines may have been more likely to be prescribed to patients with anxiety of 
greater severity. Thus, the association between receipt of benzodiazepines and overdose 
death may be partially explained by these underlying conditions or the severity of those 
conditions.  
We attempted to address confounding by indication and severity in two ways. 
Baseline patient characteristics, including demographic information, medical and mental 
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health diagnoses, and the daily opioid dose were adjusted for in a multivariable model. 
Additionally, by distinguishing between periods of current and former receipt of 
benzodiazepines, we addressed some unmeasured confounding. Nonetheless, because 
those with current receipt of benzodiazepines may have had more severe conditions for 
which benzodiazepines were prescribed than those with former receipt, some residual 
confounding may exist. Patients with greater substance use or psychiatric severity may be 
more likely to take any medication in greater quantities than prescribed, as well as illicit 
drugs, leading to an increased risk of overdose death.  
It is unclear through our analysis the degree to which benzodiazepines contributed 
to the actual cause of overdose death. Half of the overdose deaths occurred during periods 
when benzodiazepines were not prescribed, and although the risk of overdose death 
increased in a benzodiazepine dose-response fashion, this may reflect an effect of greater 
psychiatric severity or other differences between patients who did and did not receive 
benzodiazepines, rather than the benzodiazepine itself. Thus it is important to note that 
within the present study, benzodiazepines might be better conceptualized as a marker of 
risk with unknown direct causal links to overdose death. 
We found that the risk of overdose death was increased during periods of former 
benzodiazepine receipt. In addition to having a greater risk of overdose death because of 
having the underlying conditions for which benzodiazepines are prescribed, the increased 
risk of overdose death in those formerly prescribed benzodiazepines may be explained by 
continued use of benzodiazepines obtained illicitly or through non-VHA providers. 
Although we found that expanding the period in which veterans were currently being 
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prescribed benzodiazepines had a negligible impact on risk of overdose death, those 
formerly prescribed benzodiazepines may still have had leftover benzodiazepine 
medications that they continued to use well past the end date of their prescription.  
 Benzodiazepines are often prescribed for patients also receiving high doses of 
opioid analgesics.7,8 Studies across a number of clinical samples and with varying 
methods (including the present sample) have now replicated a finding of an association 
between opioid dose and risk of overdose death.6, 18, 41 Our findings further demonstrate 
that this association is not due to confounding by benzodiazepine prescription history, or 
by several control covariates we included here that were not included in the prior study in 
this sample.18 The association of opioid dose with overdose death did not appear to differ 
by benzodiazepine prescription history.  
Although receipt of benzodiazepines and the benzodiazepine dose were associated 
with increased overdose death risk, the benzodiazepine formulation and dosing schedule 
were found to be largely unrelated after adjusting for potential confounders. 
Temazepam42 and alprazolam43 have been associated with increased toxicity compared to 
other benzodiazepines in studies of deliberate self-poisonings involving benzodiazepines. 
In contrast, we found that, when compared to clonazepam, temazepam was associated 
with a decreased overdose death risk. Possible explanations are the pharmacokinetics of 
the medications and selection factors related to the use of temazepam. For example, 
temazepam is commonly used as a treatment for insomnia44 and it is possible that 
benzodiazepines solely used to treat insomnia are associated with a lesser risk of overdose 
death. More research is needed to understand why temazepam was associated with a 
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lower risk of overdose death. Although there is limited evidence that an as-needed 
benzodiazepine dosing schedule may pose risks for patients, particularly in the elderly 
and those with substance use disorders45, 46, no association was found between as-needed 
dosing and overdose death risk when compared to regularly scheduled dosing after 
adjusting for potential confounders. 
 
Unanswered questions and future research 
Although the design of this study does not allow for the determination of the 
extent to which benzodiazepines cause overdose deaths, it does indicate a need for 
clinicians to be aware of the increased risk of overdose death among patients currently 
receiving benzodiazepines and opioids and that the risk may be higher among those 
receiving higher doses of either or both medications. This risk may be due to risks 
inherent to those prescribed benzodiazepines, such as the presence of an anxiety 
condition, and/or to the benzodiazepine itself. Thus, clinicians might take caution when 
prescribing benzodiazepines to this group. Future research may involve examining 
subgroups of the population studied here in order to find groups of patients that may be at 
greater risk of overdose death. It may be useful to know the indications for which the 
benzodiazepines were prescribed in patients receiving opioid analgesics and whether 
safer alternative medications had already been used by patients. Characteristics of 
providers that are associated with prescribing benzodiazepines to patients receiving 
opioid analgesics may help direct intervention efforts aimed at reducing benzodiazepine 
prescribing to this population. Additionally, although it is unknown whether patients with 
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comorbid pain and anxiety who use opioids and benzodiazepines would benefit from the 
same interventions to reduce overdose death risk as patients using opioids alone, 
clinicians might consider including this group in overdose prevention efforts, such as 
naloxone training for caregivers.47 Ultimately in order to help determine the benefits and 
harms of benzodiazepine use in patients receiving opioid analgesics, a randomized 
controlled trial in which the experimental arm received a benzodiazepine would need to 
be conducted in a sample of patients who had an indication for benzodiazepine treatment 




 In this observational study of a large, national cohort of veterans who received 
opioid analgesics, receipt of concurrent benzodiazepines was associated with increased 
risk of drug overdose death in a dose-response fashion. Temazepam was associated with a 
lesser risk of overdose death compared to clonazepam. Benzodiazepine schedule was not 
associated with an increased risk overdose death. The risks and benefits of 
benzodiazepine prescribing in this population warrant both caution and further 
evaluation. 
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